secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRONWOOD PHARMACEUTICALS INC (IRWD)
CIK:        0001446847
Form:       8-K
Filed at:   2026-08-06T11:12:23+00:00
Accession:  0001104659-26-091625
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ironwood raises FY2026 guidance after strong Q2; LINZESS sales up 44% YTD
-------------------------------------------------------------------------

- Q2 total revenue $113M, GAAP net income $51M ($0.31 diluted EPS), adjusted EBITDA $83M.
- LINZESS U.S. net sales Q2 $282M, YTD $555M (+44% YoY).
- FY2026 guidance raised: LINZESS net sales $1.15-1.20B, total revenue $460-485M, adjusted EBITDA >$310M.
- Repaid $200M convertible notes with cash on hand; balance sheet strengthening.
- Confirmatory Phase 3 STARS-2 trial of apraglutide in SBS-IF actively recruiting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1446847/000110465926091625/0001104659-26-091625-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1446847/000110465926091625/tm2622244d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-091625

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer